MCRB
Seres TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade D from latest DB weights. Momentum 50.4 / Value 44.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
50
Value
44
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum50 · Δ7d -
Value44 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
50
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
60% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 50.4 / Value 44.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$51.62M
Beta
0.22
Shares Out
9.68M
P/E (TTM)
25.8
P/S (TTM)
391.50
P/FCF (TTM) · Derived
-1.17
Rev YoY
-100.0%
EPS YoY
-155.4%
Gross Margin
-234.6%
Op Margin
-11825.6%
Net Debt
$37.2M
Current Ratio
1.65
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology